BioSphere's tumour therapy:
This article was originally published in Clinica
Executive Summary
US firm Biosphere has received FDA 510(k) approval for its proprietary device for treating hypervascularised tumours and peripheral arteriovenous malformations using embolisation therapy. The device - QuadraSphere Microspheres - is introduced into the blood vessels that supply hypervascularised tumours using an image-guided minimally-invasive technique. US shipments of the product are expected to begin immediately. The technology is already marketed in Europe under the name HepaSphere for treating primary and metastatic liver cancer. However, the US FDA requires that the company run further US clinical trials before it can be promoted specifically for use for this indication. The Rockland, Massachusetts company claims to have pioneered the use of microsphere embolisation technologies for treating symptomatic uterine fibroids.
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.